Dare Bioscience Inc

NASDAQ:DAREUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.

Contact Information

Headquarters

3655 Nobel Dr Ste 260SAN DIEGO, CA, United States 92122-1050

Phone

858-926-7655

Fax

302-636-5454

Executives

Independent Chairman of the Board

William Rastetter

President, Chief Executive Officer, Principal Financial Officer, Company Secretary, Director

Sabrina Johnson

Independent Director

Cheryl Blanchard

Independent Director

Jessica Grossman

Independent Director

Susan Kelley